IT1314185B1 - Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi - Google Patents

Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi

Info

Publication number
IT1314185B1
IT1314185B1 IT1999MI001826A ITMI991826A IT1314185B1 IT 1314185 B1 IT1314185 B1 IT 1314185B1 IT 1999MI001826 A IT1999MI001826 A IT 1999MI001826A IT MI991826 A ITMI991826 A IT MI991826A IT 1314185 B1 IT1314185 B1 IT 1314185B1
Authority
IT
Italy
Prior art keywords
pharmaceutical composition
aqueous media
soluble
administration
actively
Prior art date
Application number
IT1999MI001826A
Other languages
English (en)
Italian (it)
Inventor
Bruijn Karel De
Gunter Engel
Hans-Jurgen Pfannkuche
Michael Thewissen
Christian Vitzling
Othmar Zuger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1314185(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9818340.3A external-priority patent/GB9818340D0/en
Priority claimed from GBGB9823477.6A external-priority patent/GB9823477D0/en
Priority claimed from GBGB9910320.2A external-priority patent/GB9910320D0/en
Priority claimed from GBGB9911059.5A external-priority patent/GB9911059D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ITMI991826A0 publication Critical patent/ITMI991826A0/it
Publication of ITMI991826A1 publication Critical patent/ITMI991826A1/it
Application granted granted Critical
Publication of IT1314185B1 publication Critical patent/IT1314185B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IT1999MI001826A 1998-08-21 1999-08-19 Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi IT1314185B1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9818340.3A GB9818340D0 (en) 1998-08-21 1998-08-21 Organic compounds
GBGB9823477.6A GB9823477D0 (en) 1998-10-27 1998-10-27 Organic compounds
GBGB9910320.2A GB9910320D0 (en) 1999-05-05 1999-05-05 Organic compounds
GBGB9911059.5A GB9911059D0 (en) 1999-05-12 1999-05-12 Organic compounds

Publications (3)

Publication Number Publication Date
ITMI991826A0 ITMI991826A0 (it) 1999-08-19
ITMI991826A1 ITMI991826A1 (it) 2001-02-19
IT1314185B1 true IT1314185B1 (it) 2002-12-06

Family

ID=27451823

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1999MI001826A IT1314185B1 (it) 1998-08-21 1999-08-19 Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi

Country Status (30)

Country Link
US (4) US20030236183A1 (da)
EP (1) EP1104289B1 (da)
JP (1) JP4048024B2 (da)
KR (1) KR100529659B1 (da)
CN (2) CN1589906A (da)
AT (1) ATE316782T1 (da)
AU (4) AU762829B2 (da)
BG (1) BG65322B1 (da)
BR (1) BR9913135A (da)
CA (1) CA2338794C (da)
CZ (1) CZ300647B6 (da)
DE (1) DE69929703T2 (da)
DK (1) DK1104289T3 (da)
EE (1) EE05054B1 (da)
ES (1) ES2257869T3 (da)
FR (3) FR2782454B1 (da)
HK (1) HK1038179A1 (da)
HR (1) HRP20010123B1 (da)
HU (1) HU228179B1 (da)
ID (1) ID28510A (da)
IL (1) IL141236A0 (da)
IS (1) IS2369B (da)
IT (1) IT1314185B1 (da)
NO (1) NO328756B1 (da)
NZ (1) NZ509832A (da)
PL (2) PL194069B1 (da)
RS (1) RS50104B (da)
SK (1) SK285255B6 (da)
TR (3) TR200100361T2 (da)
WO (1) WO2000010526A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004411A1 (en) 2000-07-07 2002-01-17 The Administrators Of The Tulane Educational Fund Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
US20040096423A1 (en) * 2000-11-24 2004-05-20 Megens Antonius Adrianus Hendrikus Petrus Use of a triple combination comprising a 5ht3 antagonist, a 5ht4agonist and a laxative for promoting intestinal lavage
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
WO2004075913A1 (ja) * 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha タンパク質含有安定化製剤
US20050119328A1 (en) * 2003-03-25 2005-06-02 Hetero Drugs Limited Novel crysalline forms of tegaserod maleate
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
AR045081A1 (es) * 2003-07-24 2005-10-12 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
US8389032B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US8591974B2 (en) 2003-11-21 2013-11-26 Kraft Foods Global Brands Llc Delivery system for two or more active components as part of an edible composition
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
CA2629904C (en) 2005-11-28 2018-07-10 Imaginot Pty Ltd. Oral therapeutic compound delivery system
TR201902233T4 (tr) 2009-10-30 2019-03-21 Ix Biopharma Ltd Hızlı çözünen katı dozaj formu.
US20140296831A1 (en) 2011-08-20 2014-10-02 Fred Göbel Trans-anal inflow catheter and method for intermittently triggering a reflex-coordinated defecation
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US552398A (en) * 1895-12-31 Riveting-machine
JP2708803B2 (ja) * 1987-09-02 1998-02-04 中外製薬株式会社 持続放出製剤
ATE123237T1 (de) * 1990-08-24 1995-06-15 Spirig Ag Verfahren zur herstellung von pellets.
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
US20020128172A1 (en) * 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
FR2710915B1 (fr) * 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
TW270114B (da) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
EP0804169A4 (en) * 1994-12-01 1998-08-19 Cibus Pharmaceutical Inc NSAID ADMINISTRATION USING A POWDERED HYDROCOLLOID GUM MACHINABLE FROM HIGHER PLANTS
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
FR2753196B1 (fr) * 1996-09-12 1998-10-23 Synthelabo Derives d'indazole tricyclique, leur preparation et leur application en therapeutique
KR100775154B1 (ko) * 1997-12-19 2007-11-12 스미스클라인 비참 코포레이션 바이트-분산성 정제의 제조 방법
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod

Also Published As

Publication number Publication date
NZ509832A (en) 2003-11-28
CN1589906A (zh) 2005-03-09
AU2003248212A1 (en) 2003-10-30
NO328756B1 (no) 2010-05-03
TR200400187T2 (tr) 2006-11-21
HK1038179A1 (en) 2002-03-08
HUP0103431A3 (en) 2002-02-28
FR2799123B1 (fr) 2005-12-02
EP1104289A2 (en) 2001-06-06
HRP20010123A2 (en) 2002-02-28
FR2782454B1 (fr) 2005-12-02
CZ300647B6 (cs) 2009-07-08
IS2369B (is) 2008-06-15
AU762829B2 (en) 2003-07-03
KR100529659B1 (ko) 2005-11-21
AU5623299A (en) 2000-03-14
BG105257A (en) 2001-11-30
PL200132B1 (pl) 2008-12-31
JP2002523351A (ja) 2002-07-30
ITMI991826A1 (it) 2001-02-19
FR2784899A1 (fr) 2000-04-28
FR2782454A1 (fr) 2000-02-25
FR2799123A1 (fr) 2001-04-06
NO20010863D0 (no) 2001-02-20
PL346764A1 (en) 2002-02-25
CA2338794A1 (en) 2000-03-02
PL194069B1 (pl) 2007-04-30
BR9913135A (pt) 2001-05-08
RS50104B (sr) 2009-01-22
HUP0103431A2 (hu) 2002-01-28
DE69929703T2 (de) 2007-02-22
EP1104289B1 (en) 2006-02-01
EE05054B1 (et) 2008-08-15
AU2009200403A1 (en) 2009-02-26
IL141236A0 (en) 2002-03-10
US20080075773A1 (en) 2008-03-27
ATE316782T1 (de) 2006-02-15
US20130158092A1 (en) 2013-06-20
AU2006200048A1 (en) 2006-02-02
JP4048024B2 (ja) 2008-02-13
CN1323200A (zh) 2001-11-21
HU228179B1 (en) 2013-01-28
SK285255B6 (sk) 2006-09-07
ES2257869T3 (es) 2006-08-01
TR200100361T2 (tr) 2001-06-21
TR200102259T2 (tr) 2002-06-21
DK1104289T3 (da) 2006-05-15
CZ2001619A3 (en) 2001-05-16
IS5851A (is) 2001-01-20
US20120071537A1 (en) 2012-03-22
NO20010863L (no) 2001-03-26
EE200100104A (et) 2002-06-17
BG65322B1 (bg) 2008-02-29
FR2784899B1 (fr) 2001-08-17
WO2000010526A3 (en) 2000-09-08
HRP20010123B1 (en) 2010-11-30
WO2000010526A2 (en) 2000-03-02
SK2432001A3 (en) 2001-09-11
KR20010079668A (ko) 2001-08-22
ID28510A (id) 2001-05-31
US20030236183A1 (en) 2003-12-25
CN1165293C (zh) 2004-09-08
CA2338794C (en) 2009-01-20
YU8701A (sh) 2003-12-31
ITMI991826A0 (it) 1999-08-19
DE69929703D1 (de) 2006-04-13

Similar Documents

Publication Publication Date Title
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
NZ501950A (en) Medicinal compositions for application to mucosa
HK1097449A1 (en) Methods for in vivo delivery of biologics and compositions useful therefor
ES2133785T3 (es) Inhibidores de metaloproteinasas.
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
ES2195344T3 (es) Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico.
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
UY27373A1 (es) Formulaciones de interferón beta-humano
PT1178787E (pt) Composicoes farmacologicas para administracao por via oral de floroglucinol e suas preparacoes
ATE226065T1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
DK1231908T3 (da) Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf
DE60007074D1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
FR2751967B1 (fr) Agents antipaludeens et antibabesioses et compositions pharmaceutiques les contenant
MY152490A (en) New oral formulation
ECSP993104A (es) Nueva formulacion oral
CR6300A (es) Nueva formulacion oral